WHO Drug Information, Vol. 24, No. 3, 2010                                                Recommended INN: List 64



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 64
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in Cumulative List
No. 13, 2009 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 64
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans
la Liste récapitulative No. 13, 2009 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 64
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han
sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en
las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran
reunidas en Cumulative List No. 13, 2009 (disponible sólo en CD-ROM).


                                                                                                                 259
Recommended INN: List 64                                                    WHO Drug Information, Vol. 24, No. 3, 2010




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 acidum zibrofusidicum
 zibrofusidic acid                         (17Z)-16β-(acetyloxy)-24-bromo-3α,11α-dihydroxy-29-norprotosta-
                                           17(20),24-dien-21-oic acid

 acide zibrofusidique                      acide (17Z)-16β-(acétyloxy)-24-bromo-3α,11α-dihydroxy-
                                           29-norprotosta-17(20),24-dién-21-oïque

 ácido zibrofusídico                       ácido (17Z)-16β-(acetiloxi)-24-bromo-3α,11α-dihidroxi-
                                           29-norprotosta-17(20),24-dien-21-oico

                                           C31H47BrO6

                                                        H3 C          Br

                                                        H3 C
                                                             H        H        CO2H
                                                        HO
                                                                               O       CH3
                                                          CH3    CH3
                                                                               H
                                                                                   O
                                             H               H        CH3
                                            HO
                                                  H     H
                                                      CH3



 afatinibum
 afatinib                                  (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-{[(3S)-oxolan-
                                           3-yl]oxy}quinoxazolin-6-yl]-4-(dimethylamino)but-2-enamide

 afatinib                                  (2E)-N-[4-(3-chloro-4-fluoroanilino]-7-{[(3S)-oxolan-
                                           3-yl]oxy}quinoxazolin-6-y]-4-(diméthylamino)but-2-énamide

 afatinib                                  (2E)-N-[4-(3-cloro-4-fluoroanilino)-7-{[(3S)-oxolan-
                                           3-il]oxi}quinoxazolin-6-il]-4-(dimetilamino)but-2-enamida

                                           C24H25ClFN5O3

                                                      O          O             N
                                                                  H
                                                                                   N
                                                  CH3            HN
                                                  N                           HN             Cl
                                            H3C                       O

                                                                                             F




260
WHO Drug Information, Vol. 24, No. 3, 2010                                               Recommended INN: List 64


 atagabalinum
 atagabalin                                  [(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopent-1-yl]acetic acid

 atagabaline                                 acide [(3S,4S)-1-(aminométhyl)-3,4-diméthylcyclopent-1-yl]acétique

 atagabalina                                 ácido [(3S,4S)-1-(aminometil)-3,4-dimetilciclopent-1-il]acético

                                             C10H19NO2

                                             H2 N           CO2H


                                              H3C           CH3
                                                    H   H



 barasertibum
 barasertib                                  2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-
                                             3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen
                                             phosphate

 barasertib                                  dihydrogénophosphate de 2-{éthyl[3-({4-[(5-{2-[(3-
                                             fluorophényl)amino]-2-oxoéthyl}-1H-pyrazol-3-yl)amino]quinazolin-
                                             7-yl}oxy)propyl]aminoéthyle

 barasertib                                  dihidrógenofosfato de 2-{etil[3-({4-[(5-{2-[(3-fluorofenil)amino]-
                                             2-oxoetil}-1H-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}etilo

                                             C26H31F N7O6P

                                                                  CH3
                                             HO OH
                                               P             N           O           N
                                             O   O
                                                                                         N
                                                                                                        H
                                                                                    HN                  N          F

                                                                                         N   NH     O


 benralizumabum #
 benralizumab                                immunoglobulin G1-kappa, anti-[Homo sapiens IL5RA (interleukin 5
                                             receptor subunit alpha, CD125)], humanized monoclonal
                                             antibody;gamma1 heavy chain (1-451) [humanized VH (Homo
                                             sapiens IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -
                                             Homo sapiens IGHG1*01 (122-451)], (224-214')-disulfide with kappa
                                             light chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-
                                             39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                                             (108'-214')]; (230-230":233-233")-bisdisulfide dimer

 benralizumab                                immunoglobuline G1-kappa, anti-[Homo sapiens ILR5A (sous-unité
                                             alpha du récepteur de l'interleukine 5, CD125)], anticorps
                                             monoclonal humanisé; chaîne lourde gamma1 (1-451) [VH
                                             humanisé (Homo sapiens IGHV1-46*01 (78.60%) -(IGHD)-
                                             IGHJ4*01) [8.8.14] (1-121) -Homo sapiens IGHG1*01 (122-451)],
                                             (224-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA
                                             humanisé (Homo sapiens IGKV1-39*01 (87.40%) -IGKJ2*01) [6.3.9]
                                             (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (230-
                                             230":233-233")-bisdisulfure




                                                                                                                       261
Recommended INN: List 64                                      WHO Drug Information, Vol. 24, No. 3, 2010




 benralizumab              inmunoglobulina G1-kappa, anti-[Homo sapiens ILR5A (subunidad
                           alfa del receptor de la interleukina 5, CD125)], anticuerpo
                           monoclonal humanizado;
                           cadena pesada gamma1 (1-451) [VH humanizada (Homo sapiens
                           IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo
                           sapiens IGHG1*01 (122-451)], (224-214')-disulfuro con la cadena
                           ligera kappa (1'-214') [V-KAPPA humanizada (Homo sapiens IGKV1-
                           39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           (108'-214')]; dímero (230-230":233-233")-bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVQSGAE VKKPGASVKV SCKASGYTFT                  SYVIHWVRQR       PGQGLAWMGY        50
                           INPYNDGTKY NERFKGKVTI TSDRSTSTVY                  MELSSLRSED       TAVYLCGREG       100
                           IRYYGLLGDY WGQGTLVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ       200
                           TYICNVNHKP SNTKVDKKVE PKSCDKTHTC                  PPCPAPELLG       GPSVFLFPPK       250
                           PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY       300
                           NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP       350
                           QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                           VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG       450
                           K                                                                                   451

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCGTSEDII                  NYLNWYQQKP       GKAPKLLIYH 50
                           TSRLQSGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       GYTLPYTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        148-204       265-325  371-429
                                    22''-96'' 148''-204'' 265''-325'' 371''-429''
                           Intra-L 23'-88'       134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 224-214' 224''-214'''
                           Inter-H-H 230-230'' 233-233''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           301, 301''




 cabiotraxetanum
 cabiotraxetan             2,2',2''-[10-(2-{[6-({5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
                           d]imidazol-4-yl]pentyl}amino)hexyl]amino}-2-oxoethyl)-1,4,7,10-
                           tetraazacyclododecane-1,4,7-triyl]triacetic acid

 cabiotraxétan             acide 2,2',2''-[10-(2-{[6-({5-[(3aS,4S,6aR)-2-oxohexahydro-
                           1H--thiéno[3,4-d]imidazol-4-yl]pentyl}amino)hexyl]amino}-
                           2-oxoéthyl)-1,4,7,10-tétraazacyclododécane-1,4,7-triyl]triacétique

 cabiotraxetán             ácido [10-(2-{[6-({5-[(3aS,4S,6aR)-2-oxohexahidro-1H-tieno[3,4-
                           d]imidazol-4-il]pentil}amino)hexil]amino}-2-oxoetil)-1,4,7,10-
                           tetraazaciclododecano-1,4,7-triilo]triacético

                           C32H58N8O8S

                                                               H
                                                               N
                           HO2C         N         N                                      N
                                                                                       H H
                                                          O                   H H
                                                                              N
                           HO2C         N         N        CO2H        O                  S
                                                                              N
                                                                              H H




262
WHO Drug Information, Vol. 24, No. 3, 2010                                                Recommended INN: List 64




 canagliflozinum
 canagliflozin                               (1S)-1,5-anhydro-1-C-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-
                                             4-methylphenyl)-D-glucitol

 canagliflozine                              (1S)-1,5-anhydro-1-C-(3-{[5-(4-fluorophényl)thiophén-2-yl]méthyl}-
                                             4-méthylphényl)-D-glucitol

 canagliflozina                              (1S)-1,5-anhidro-1-C-(3-{[5-(4-fluorofenil)tiofen-2-il]metil}-
                                             4-metilfenil)-D-glucitol

                                             C24H25FO5S

                                                                     F




                                                          S
                                                               CH3

                                             HO

                                                           O
                                                     OH
                                             HO
                                                           OH




 carotegrastum
 carotegrast                                 (2S)-2-(2,6-dichlorobenzamido)-3-{4-[6-(dimethylamino)-1-methyl-
                                             2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]phenyl}propanoic acid

 carotégrast                                 acide (2S)-2-(2,6-dichlorobenzamido)-3-{4-[6-(diméthylamino)-
                                             1-méthyl-2,4-dioxo-1,4-dihydroquinazolin-
                                             3(2H)-yl]phényl}propanoïque

 carotegrast                                 ácido (2S)-2-(2,6-diclorobenzamido)-3-{4-[6-(dimetilamino)-1-metil-
                                             2,4-dioxo-1,4-dihidroquinazolin-3(2H)-il]fenil}propanoico

                                             C27H24Cl2N4O5

                                                          Cl
                                                               H
                                                               N
                                                                                  O         CH3
                                                               H
                                                Cl        O        CO2H                     N
                                                                              N                 CH3

                                                                          O       N
                                                                                  CH3




                                                                                                                   263
Recommended INN: List 64                              WHO Drug Information, Vol. 24, No. 3, 2010


 condoliasum #
 condoliase                endolyase, chondroitin ABC (C-ABC). glycosaminoglycan lyase
                           chondroitin ABC endolyase 1 (chondroitinase ABC) Proteus vulgaris

 condoliase                endolyase, chondroïtine ABC (C-ABC). glycosaminoglycane lyase
                           chondroïtine ABC endolyase 1 (chondroïtinase ABC) Proteus
                           vulgaris

 condoliasa                endoliasa, condroitina ABC (C-ABC). glicosaminoglicano liasa
                           condroitina ABC endoliasa 1 (condroitinasa ABC) Proteus vulgaris

                           C5039H7770N1360O1525S22

                           ATSNPAFDPK    NLMQSEIYHF     AQNNPLADFS   SDKNSILTLS   DKRSIMGNQS     50
                           LLWKWKGGSS    FTLHKKLIVP     TDKEASKAWG   RSSTPVFSFW   LYNEKPIDGY    100
                           LTIDFGEKLI    STSEAQAGFK     VKLDFTGWRA   VGVSLNNDLE   NREMTLNATN    150
                           TSSDGTQDSI    GRSLGAKVDS     IRFKAPSNVS   QGEIYIDRIM   FSVDDARYQW    200
                           SDYQVKTRLS    EPEIQFHNVK     PQLPVTPENL   AAIDLIRQRL   INEFVGGEKE    250
                           TNLALEENIS    KLKSDFDALN     IHTLANGGTQ   GRHLITDKQI   IIYQPENLNS    300
                           QDKQLFDNYV    ILGNYTTLMF     NISRAYVLEK   DPTQKAQLKQ   MYLLMTKHLL    350
                           DQGFVKGSAL    VTTHHWGYSS     RWWYISTLLM   SDALKEANLQ   TQVYDSLLWY    400
                           SREFKSSFDM    KVSADSSDLD     YFNTLSRQHL   ALLLLEPDDQ   KRINLVNTFS    450
                           HYITGALTQV    PPGGKDGLRP     DGTAWRHEGN   YPGYSFPAFK   NASQLIYLLR    500
                           DTPFSVGESG    WNNLKKAMVS     AWIYSNPEVG   LPLAGRHPFN   SPSLKSVAQG    550
                           YYWLAMSAKS    SPDKTLASIY     LAISDKTQNE   STAIFGETIT   PASLPQGFYA    600
                           FNGGAFGIHR    WQDKMVTLKA     YNTNVWSSEI   YNKDNRYGRY   QSHGVAQIVS    650
                           NGSQLSQGYQ    QEGWDWNRME     GATTIHLPLK   DLDSPKPHTL   MQRGERGFSG    700
                           TSSLEGQYGM    MAFNLIYPAN     LERFDPNFTA   KKSVLAADNH   LIFIGSNINS    750
                           SDKNKNVETT    LFQHAITPTL     NTLWINGQKI   ENMPYQTTLQ   QGDWLIDSNG    800
                           NGYLITQAEK    VNVSRQHQVS     AENKNRQPTE   GNFSSAWIDH   STRPKDASYE    850
                           YMVFLDATPE    KMGEMAQKFR     ENNGLYQVLR   KDKDVHIILD   KLSNVTGYAF    900
                           YQPASIEDKW    IKKVNKPAIV     MTHRQKDTLI   VSAVTPDLNM   TRQKAATPVT    950
                           INVTINGKWQ    SADKNSEVKY     QVSGDNTELT   FTSYFGIPQE   IKLSPLP       997



 dalotuzumabum #
 dalotuzumab               immunoglobulin G1-kappa, anti-[Homo sapiens IGF1R (insulin-like
                           growth factor 1 receptor, IGF1-R, IGF-1R, CD221], humanized
                           monoclonal antibody;
                           gamma1 heavy chain (1-447) [humanized VH (Homo sapiens
                           IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo
                           sapiens IGHG1*03 (118-447)], (220-219')-disulfide with kappa light
                           chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-29*02
                           (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01
                           (113'-219')]; (226-226":229-229")-bisdisulfide dimer

 dalotuzumab               immunoglobuline G1-kappa, anti-[Homo sapiens IGF1R (récepteur
                           du facteur de croissance 1 analogue à l'insuline (IGF1-R, IGF-1R,
                           CD221)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens
                           IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo
                           sapiens IGHG1*03 (118-447)], (220-219')-disulfure avec la chaîne
                           légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-
                           29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens
                           IGKC*01 (113'-219')]; dimère (226-226":229-229")-bisdisulfure

 dalotuzumab               inmunoglobulina G1-kappa, anti-[Homo sapiens IGF1R (receptor del
                           factor de crecimiento similar a la insulina 1(IGF1-R, IGF-1R,
                           CD221)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-447) [VH humanizada (Homo sapiens
                           IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo
                           sapiens IGHG1*03 (118-447)], (220-219')-disulfuro con la cadena
                           ligera kappa (1'-219') [V-KAPPA humanizada (Homo sapiens IGKV2-
                           29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens
                           IGKC*01 (113'-219')]; dímero (226-226":229-229")-bisdisulfuro




264
WHO Drug Information, Vol. 24, No. 3, 2010                                                           Recommended INN: List 64




                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLQQSGPG LVKPSQTLSL TCTVSGWSIS                  GGWLWNWIRQ       PPGKGLQWIG        50
                                             WISWDGTNNW KPSLKDRVTI SVDTSKNQFS                  LKLSSVTAAD       TAVWWCARWG       100
                                             RVFFDWWGQG TLVTVSSAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                                             PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                                             NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP                  APELLGGPSV       FLFPPKPKDT       250
                                             LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                                             RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  PIEKTISKAK       GQPREPQVYT       350
                                             LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                                             DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIVMTQSPLS LPVTPGQPAS ISCRSSQSIV                  HSNGNTWLQW       WLQKPGQSPQ 50
                                             LLIWKVSNRL WGVPDRFSGS GSGTDFTLKI                  SRVQAQDVGV       WWCFQGSHVP 100
                                             WTFGQGTKVQ IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                             VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                             VTHQGLSSPV TKSFNRGEC                                                          219

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96 144-200              261-321  367-425
                                                      22''-96'' 144''-200'' 261''-321'' 367''-425''
                                             Intra-L 23'-93'      139'-199'
                                                      23'''-93''' 139'''-199'''
                                             Inter-H-L 220-219' 220''-219'''
                                             Inter-H-H 226-226'' 229-229''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             297, 297''


 danoprevirum
 danoprevir                                  (2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-
                                             14a-[N-(cyclopropanesulfonyl)carbamoyl]-5,16-dioxo-
                                             1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
                                             hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-
                                             2-yl 4-fluoro-1,3-dihydro-2H-isoindole-2-carboxylate

 danoprévir                                  4-fluoro-1,3-dihydro-2H-isoindole-2-carboxylate de
                                             (2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-
                                             14a-[N-(cyclopropanesulfonyl)carbamoyl]-5,16-dioxo-
                                             1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
                                             hexadécahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadécin-
                                             2-yle

 danoprevir                                  4-fluoro-1,3-dihidro-2H-isoindol-2-carboxilato de
                                             (2R,6S,12Z,13aS,14aR,16aS)-6-[(terc-butoxicarbonil)amino]-
                                             14a-[N-(ciclopropanosulfonil)carbamoil]-5,16-dioxo-
                                             1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
                                             hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-
                                             2-ilo

                                             C35H46FN5O9S

                                                          O
                                                      O       S
                                                  O           NH
                                                                   O
                                                                       H
                                                                                   O
                                                              N                H
                                                              H                                      F
                                                  H                    N       O   N
                                                              O
                                                                               CH3
                                                                        H O
                                                                                 CH3
                                                                   HN          CH3
                                                                           O




                                                                                                                                       265
Recommended INN: List 64                                  WHO Drug Information, Vol. 24, No. 3, 2010


 derenofyllinum
 derenofylline             trans-4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-
                           4-yl)amino]cyclohexanol

 dérénofylline             trans-4-[(2-phényl-7H-pyrrolo[2,3-d]pyrimidin-
                           4-yl)amino]cyclohexanol

 derenofilina              trans-4-[(2-fenil-7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclohexanol

                           C18H20N4O


                                                  H
                                         N        N

                                     N
                                                             OH
                                         HN



 dilmapimodum
 dilmapimod                8-(2,6-difluorophenyl)-2-[(1,3-dihydroxypropan-2-yl)amino]-
                           4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7(8H)-one

 dilmapimod                8-(2,6-difluorophényl)-2-[(1,3-dihydroxypropan-2-yl)amino]-
                           4-(4-fluoro-2-méthylphényl)pyrido[2,3-d]pyrimidin-7(8H)-one

 dilmapimod                8-(2,6-difluorofenil)-2-[(1,3-dihidroxipropan-2-il)amino]-4-(4-fluoro-
                           2-metilfenil)pirido[2,3-d]pirimidin-7(8H)-ona

                           C23H19F3N4O3

                                                  F




                                     H3C
                                HO
                                              N
                           HO
                                         N        N   N      O
                                         H
                                                  F          F




 dinaciclibum
 dinaciclib                3-[({3-ethyl-5-[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-
                           a]pyrimidin-7-yl}amino)methyl]pyridine 1-oxide

 dinaciclib                1-oxyde de 3-[({3-éthyl-5-[(2S)-2-(2-hydroxyéthyl)pipéridin-
                           1-yl]pyrazolo[1,5-a]pyrimidin-7-yl}amino)méthyl]pyridine

 dinaciclib                1-óxido de 3-[({3-etil-5-[(2S)-2-(2-hidroxietil)piperidin-
                           1-il]pirazolo[1,5-a]pirimidin-7-il}amino)metil]piridina




266
WHO Drug Information, Vol. 24, No. 3, 2010                                                 Recommended INN: List 64


                                             C21H28N6O2


                                                                         H
                                                            N            N         N
                                                                                       O
                                                         H       N   N
                                             HO                          N

                                                         H3C




 dipraglurantum
 dipraglurant                                6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-a]pyridine

 dipraglurant                                6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-a]pyridine

 dipraglurant                                6-fluoro-2-[4-(piridin-2-il)but-3-in-1-il]imidazo[1,2-a]piridina

                                             C16H12FN3

                                                   N



                                                                             N
                                                                     N            F




 duvoglustatum
 duvoglustat                                 (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol

 duvoglustat                                 (2R,3R,4R,5S)-2-(hydroxyméthyl)pipéridine-3,4,5-triol

 duvoglustat                                 (2R,3R,4R,5S)-2-(hidroximetil)piperidina-3,4,5-triol

                                             C6H13NO4

                                                       OH
                                                   H        H
                                             HO
                                               H
                                                            NH
                                             HO
                                                            H
                                                         OH



 efatutazonum
 efatutazone                                 rac-5-[(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-
                                             1H-benzimidazol-2-yl]methoxy}phenyl)methyl]-1,3-thiazolidine-
                                             2,4-dione

 éfatutazone                                 rac-5-[(4-{[6-(4-amino-3,5-diméthylphénoxy)-1-méthyl-
                                             1H-benzimidazol-2-yl]méthoxy}phényl)méthyl]thiazolidine-2,4-dione

 efatutazona                                 rac-5-[(4-{[6-(4-amino-3,5-dimetilfenoxi)-1-metil-1H-benzoimidazol-
                                             2-il]metoxi}fenil)metil]-1,3-tiazolidina-2,4-diona




                                                                                                                   267
Recommended INN: List 64                                   WHO Drug Information, Vol. 24, No. 3, 2010




                           C27H26N4O4S

                                H3 C

                           H2N              O

                                                               CH3                        and enantiomer
                                H3 C                       N                              et énantiomère
                                                                                     O
                                                                                          y enantiómero
                                                                     O
                                                       N                         S
                                                                                     NH

                                                                                 H   O



 emicerfontum
 emicerfont                1-{1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-
                           1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one

 emicerfont                1-{1-[1-(4-méthoxy-2-méthylphényl)-6-méthyl-2,3-dihydro-
                           1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one

 emicerfont                1-{1-[1-(4-metoxi-2-metilfenil)-6-metil-2,3-dihidro-1H-pirrolo[2,3-
                           b]piridin-4-il]-1H-pirazol-3-il}imidazolidin-2-ona

                           C22H24N6O2

                                                                   H3 C

                                   N        N                  N
                           HN           N                                 OCH3
                                   O                       N

                                                  CH3



                    18
 florbetabenum ( F)
              18                                  18
 florbetaben ( F)          4-{(1E)-2-(4-{2-[2-(2-[ F]fluoroethoxy)ethoxy]ethoxy}phenyl)eth-
                           1-en-1-yl}-N-methylaniline
               18                                 18
 florbétabène ( F)         4-{(1E)-2-(4-{2-[2-(2-[ F]fluoroéthoxy)éthoxy]éthoxy}phényl)éth-
                           1-én-1-yl}-N-méthylaniline
              18                                  18
 florbetabén ( F)          4-{(1E)-2-(4-{2-[2-(2-[ F]fluoroetoxi)etoxi]etoxi}fenil)et-1-en-1-il}-
                           N-metilanilina
                                   18
                           C21H26[ F]NO3

                                  H
                                  N
                           H3 C



                                                                          O                  [18F]
                                                                      O              O




268
WHO Drug Information, Vol. 24, No. 3, 2010                                              Recommended INN: List 64




 foretinibum
 foretinib                                   N-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-
                                             4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

 forétinib                                   N-[3-fluoro-4-({6-méthoxy-7-[3-(morpholin-4-yl)propoxy]quinoléin-
                                             4-yl}oxy)phényl]-N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

 foretinib                                   N-[3-fluoro-4-({6-metoxi-7-[3-(morfolin-4-il)propoxi]quinolin-
                                             4-il}oxi)fenil]-N'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

                                             C34H34F2N4O6

                                             O
                                                   N           O            N


                                                            H3CO
                                                                            O                                   F
                                                                                            O    O

                                                                            F           N            N
                                                                                        H            H



 glembatumumabum #
 glembatumumab                               immunoglobulin G2-kappa, anti-[Homo sapiens GPNMB
                                             (glycoprotein transmembrane NMB, hematopoietic growth factor
                                             inducible neurokinin-1 type, HGFIN) extracellular domain], Homo
                                             sapiens monoclonal antibody;
                                             gamma2 heavy chain (1-445) [Homo sapiens VH (IGHV4-31*02
                                             (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-
                                             445)], (133-215')-disulfide with kappa light chain (1'-215') [Homo
                                             sapiens V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10]
                                             (1'-108') -IGKC*01 (109'-215')]; (221-221'':222-222'':225-225'':228-
                                             228'')-tetrakisdisulfide dimer

 glembatumumab                               immunoglobuline G2-kappa, anti-[Homo sapiens GPNMB
                                             (glycoprotéine transmembranaire NMB, facteur de croissance
                                             hématopoïétique inductible type neurokinine-1, HGFIN) domaine
                                             extracellulaire], Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma2 (1-445) [Homo sapiens VH (IGHV4-31*02
                                             (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-
                                             445)], (133-215')-disulfure avec la chaîne légère kappa (1'-215')
                                             [Homo sapiens V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01)
                                             [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimère (221-221'':222-
                                             222'':225-225'':228-228'')-tétrakisdisulfure

 glembatumumab                               inmunoglobulina G2-kappa, anti-[Homo sapiens GPNMB
                                             (glicoproteína transmembranosa NMB, factor de crecimiento
                                             hematopoyético inductible tipo neuroquinina-1, HGFIN) dominio
                                             extracelular], Homo sapiens anticuerpo monoclonal;
                                             cadena pesada gamma2 (1-445) [Homo sapiens VH (IGHV4-31*02
                                             (94.90%)-(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-
                                             445)], (133-215')-disulfuro con la cadena ligera kappa (1'-215')
                                             [Homo sapiens V-KAPPA (IGKV3-15*01 (96.80%)-IGKJ1*01)
                                             [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (221-221'':222-
                                             222'':225-225'':228-228'')-tetrakisdisulfuro




                                                                                                                    269
Recommended INN: List 64                                    WHO Drug Information, Vol. 24, No. 3, 2010


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQESGPG LVKPSQTLSL TCTVSGGSIS                        SFNYYWSWIR   HHPGKGLEWI      50
                           GYIYYSGSTY SNPSLKSRVT ISVDTSKNQF                        SLTLSSVTAA   DTAVYYCARG     100
                           YNWNYFDYWG QGTLVTVSSA STKGPSVFPL                        APCSRSTSES   TAALGCLVKD     150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                        LYSLSSVVTV   PSSNFGTQTY     200
                           TCNVDHKPSN TKVDKTVERK CCVECPPCPA                        PPVAGPSVFL   FPPKPKDTLM     250
                           ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV                        EVHNAKTKPR   EEQFNSTFRV     300
                           VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI                        EKTISKTKGQ   PREPQVYTLP     350
                           PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE                        SNGQPENNYK   TTPPMLDSDG     400
                           SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL                        HNHYTQKSLS   LSPGK          445

                           Light chain / Chaîne légère / Cadena ligera
                           EIVMTQSPAT LSVSPGERAT LSCRASQSVD                        NNLVWYQQKP   GQAPRLLIYG 50
                           ASTRATGIPA RFSGSGSGTE FTLTISSLQS                        EDFAVYYCQQ   YNNWPPWTFG 100
                           QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                        ASVVCLLNNF   YPREAKVQWK 150
                           VDNALQSGNS QESVTEQDSK DSTYSLSSTL                        TLSKADYEKH   KVYACEVTHQ 200
                           GLSSPVTKSF NRGEC                                                                215

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-97 146-202              259-319  365-423
                                    22''-97'' 146''-202'' 259''-319'' 365''-423''
                           Intra-L 23'-88'      135'-195'
                                    23'''-88''' 135'''-195'''
                           Inter-H-L 133-215' 133''-215'''
                           Inter-H-H 221-221'' 222-222'' 225-225'' 228-228''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           295, 295''




 guaraprolosum
 guaraprolose              (1→6)-α-D-galactopyrano-(1→4)-β-D-mannopyranan
                           2-hydroxypropyl ether

 guaraprolose              éther 2-hydroxypropylique du (1→6)-α-D-galactopyrano-
                           (1→4)-β-D-mannopyranane

 guaraprolosa              éter 2-hidroxipropílico de (1→6)-α-D-galactopirano-
                           (1→4)-β-D-mannopiranano

                           [C18H30O15 (C3H6O)x]n

                                    HO             OR

                               HO              O

                                    HO         O                     OR

                                                   O                      O
                           H        O                       O                      OH

                                          HO           OH       HO            OH
                                                                                   n

                                         R = H, CH2-CHOH-CH3



 lasmiditanum
 lasmiditan                2,4,6-trifluoro-N-{6-[(1-methylpiperidine-4-yl)carbonyl]pyridin-
                           2-yl}benzamide

 lasmiditan                2,4,6-trifluoro-N-{6-[(1-méthylpipéridine-4-yl)carbonyl]pyridin-
                           2-yl}benzamide

 lasmiditán                2,4,6-trifluoro-N-{6-[(1-metilpiperidina-4-il)carbonil]piridin-
                           2-il}benzamida


270
WHO Drug Information, Vol. 24, No. 3, 2010                                                       Recommended INN: List 64


                                             C19H18F3N3O2

                                                                                               CH3
                                                     F     O                               N

                                                               N    N
                                                               H
                                                                               O
                                             F             F


 latrepirdinum
 latrepirdine                                2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-
                                             1H-pyrido[4,3-b]indole

 latrépirdine                                2,8-diméthyl-5-[2-(6-méthylpyridin-3-yl)éthyl]-2,3,4,5-tétrahydro-
                                             1H-pyrido[4,3-b]indole

 latrepirdina                                2,8-dimetil-5-[2-(6-metilpiridin-3-il)etil]-2,3,4,5-tetrahidro-
                                             1H-pirido[4,3-b]indol

                                             C21H25N3

                                                                           CH3




                                                                   N
                                                     N
                                                                                     N CH
                                                                                         3
                                             H 3C


 linifanibum
 linifanib                                   1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-
                                             5-methylphenyl)urea

 linifanib                                   1-[4-(3-amino-1H-indazol-4-yl)phényl]-3-(2-fluoro-
                                             5-méthylphényl)urée

 linifanib                                   1-[4-(3-amino-1H-indazol-4-il)fenil]-3-(2-fluoro-5-metilfenil)urea

                                             C21H18FN5O

                                                                                       F
                                                         NH2           H         H
                                                                       N         N
                                                 N
                                             HN                            O

                                                                                       CH3



 lunacalcipolum
 lunacalcipol                                (1S,3R,5Z,7E,23E)-24-(2-methylpropane-2-sulfonyl)-9,10-secochola-
                                             5,7,10(19),16,23-pentaene-1,3-diol

 lunacalcipol                                (1S,3R,5Z,7E,23E)-24-(2-méthylpropane-2-sulfonyl)-9,10-sécochola-
                                             5,7,10(19),16,23-pentaène-1,3-diol

 lunacalcipol                                (1S,3R,5Z,7E,23E)-24-(2-metilpropano-2-sulfonil)-9,10-secocola-
                                             5,7,10(19),16,23-pentaeno-1,3-diol




                                                                                                                      271
Recommended INN: List 64                                   WHO Drug Information, Vol. 24, No. 3, 2010


                           C28H42O4S

                                                H3C H
                                                                   H3C
                                                CH3                        CH3
                                                                   S
                                                               O           CH3
                                                                   O

                                                H


                                                CH2

                           HO                   OH
                                H           H



 mapracoratum
 mapracorat                (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-
                           4-methyl-2-{[(2-methylquinolin-5-yl)amino]methyl}pentan-2-ol

 mapracorat                (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-
                           4-méthyl-2-{[(2-méthylquinoléin-5-yl)amino]méthyl}pentan-2-ol

 mapracorat                (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihidro-1-benzofuran-7-il)-4-metil-
                           2-{[(2-metilquinolin-5-il)amino]metil}pentan-2-ol

                           C25H26F4N2O2

                           H3C
                                                        F3C OH
                                                    H
                                    N               N
                                                                       O
                                                        H3C
                                                         H3C


                                                                       F



 marizomibum
 marizomib                 (1R,4R,5S)-4-(2-chloroethyl)-1-{(S)-[(1S)-cyclohex-2-en-
                           1-yl](hydroxy)methyl}-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-
                           3,7-dione

 marizomib                 (1R,4R,5S)-4-(2-chloroéthyl)-1-{(S)-[(1S)-cyclohex-2-én-
                           1-yl](hydroxy)méthyl}-5-méthyl-6-oxa-2-azabicyclo[3.2.0]heptane-
                           3,7-dione

 marizomib                 (1R,4R,5S)-4-(2-cloroetil)-1-{(S)-[(1S)-ciclohex-2-en-
                           1-il](hidroxi)metil}-5-metil-6-oxa-2-azabiciclo[3.2.0]heptano-3,7-diona

                           C15H20ClNO4

                                                 O
                                        O        H OH
                                 H3C                H
                                  H             NH

                           Cl
                                            O




272
WHO Drug Information, Vol. 24, No. 3, 2010                                                                  Recommended INN: List 64




 mavrilimumabum #
 mavrilimumab                                immunoglobulin G4-lambda, anti-[Homo sapiens CSF2RA
                                             (granulocyte-macrophage colony-stimulating factor receptor subunit
                                             alpha, GM-CSF-R-alpha, CD116)], Homo sapiens monoclonal
                                             antibody;
                                             gamma4 heavy chain (1-447) [Homo sapiens VH (IGHV1-24*01
                                             (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)],
                                             (134-216')-disulfide with lambda light chain (1'-217') [Homo sapiens
                                             V-LAMBDA (IGLV1-40*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -
                                             IGLC2*01 (112'-217')]; (226-226'':229-229'')-bisdisulfide dimer

 mavrilimumab                                immunoglobuline G4-lambda, anti-[Homo sapiens CSF2RA (sous-
                                             unité alpha du récepteur du facteur stimulant les colonies de
                                             granulocytes et de macrophages, GM-CSF-R-alpha, CD116], Homo
                                             sapiens anticorps monoclonal;
                                             chaîne lourde gamma4 (1-447) [Homo sapiens VH (IGHV1-24*01
                                             (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)],
                                             (134-216')-disulfure avec la chaîne légère lambda (1'-217') [Homo
                                             sapiens V-LAMBDA (IGLV1-40*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-
                                             111') -IGLC2*01 (112'-217')]; dimère (226-226'':229-229'')-
                                             bisdisulfure

 mavrilimumab                                inmunoglobulina G4-lambda, anti-[CSF2RA (subunidad alfa del
                                             receptor del factor estimulante de colonias de granulocitos y
                                             macrófagos, GM-CSF-R-alfa, CD116) de Homo sapiens], anticuerpo
                                             monoclonal de Homo sapiens; cadena pesada gamma4 (1-447)
                                             [Homo sapiens VH (IGHV1-24*01 (93.80%) -(IGHD)-IGHJ3*02)
                                             [8.8.13] (1-120) -IGHG4*01 (121-447)], (134-216')-disulfuro con la
                                             cadena ligera lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV1-
                                             40*01 (87.90%)-IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')];
                                             dímero (226-226'':229-229'')-bisdisulfuro


                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQSGAE VKKPGASVKV SCKVSGYTLT                  ELSIHWVRQA       PGKGLEWMGG        50
                                             FDPEENEIVY AQRFQGRVTM TEDTSTDTAY                  MELSSLRSED       TAVYYCAIVG       100
                                             SFSPLTLGLW GQGTMVTVSS ASTKGPSVFP                  LAPCSRSTSE       STAALGCLVK       150
                                             DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTKT       200
                                             YTCNVDHKPS NTKVDKRVES KYGPPCPSCP                  APEFLGGPSV       FLFPPKPKDT       250
                                             LMISRTPEVT CVVVDVSQED PEVQFNWYVD                  GVEVHNAKTK       PREEQFNSTY       300
                                             RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS                  SIEKTISKAK       GQPREPQVYT       350
                                             LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                                             DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE                  ALHNHYTQKS       LSLSLGK          447

                                             Light chain / Chaîne légère / Cadena ligera
                                             QSVLTQPPSV SGAPGQRVTI SCTGSGSNIG                  APYDVSWYQQ       LPGTAPKLLI 50
                                             YHNNKRPSGV PDRFSGSKSG TSASLAITGL                  QAEDEADYYC       ATVEAGLSGS 100
                                             VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL                  QANKATLVCL       ISDFYPGAVT 150
                                             VAWKADSSPV KAGVETTTPS KQSNNKYAAS                  SYLSLTPEQW       KSHRSYSCQV 200
                                             THEGSTVEKT VAPTECS                                                            217

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        147-203       261-321  367-425
                                                      22''-96'' 147''-203'' 261''-321'' 367''-425''
                                             Intra-L 22'-90'      139'-198'
                                                      22'''-90''' 139'''-198'''
                                             Inter-H-L 134-216' 134''-216'''
                                             Inter-H-H 226-226'' 229-229''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             297, 297''




                                                                                                                                               273
Recommended INN: List 64                                WHO Drug Information, Vol. 24, No. 3, 2010


 moxetumomabum pasudotoxum #
 moxetumomab pasudotox         immunoglobulin Fv fragment fused to Pseudomonas toxin, anti-
                               [Homo sapiens CD22 (sialic acid-binding Ig-like lectin 2, Siglec-2,
                               SIGLEC2, Leu-14, B-lymphocyte cell adhesion molecule, BL-CAM)],
                               Mus musculus monoclonal antibody disulfide stabilized Fv fragment
                               with the variable heavy VH domain fused with the truncated form
                               PE38 of Pseudomonas aeruginosa exotoxin A (VH-PE38), disulfide
                               linked with the variable kappa domain (V-KAPPA)];
                               VH-PE38 (1-476) comprising the VH domain (1-123) [methionyl -Mus
                               musculus VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-123)]
                               fused with a 7-mer linker (124-130) and with the Pseudomonas
                               aeruginosa exotoxin A (ETA) PE38 fragment (131-476) [277-638
                               precursor fragment with del 389-405>N (131-476), containing
                               domain II (131-243) with furin proteolytic cleavage site (152-164),
                               domain Ib (244-267), domain III (268-476)], (45-101')-disulfide with
                               V-KAPPA (1'-108') [methionyl -Mus musculus V-KAPPA [(IGHKV10-
                               96*01 -IGKJ1*01) [6.3.9] (2'-108')]

 moxétumomab pasudotox         fragment Fv d'immunoglobuline fusionné à la toxine de
                               Pseudomonas, anti-[Homo sapiens CD22 (Ig-like lectine 2 liant
                               l'acide sialique, Siglec-2, SIGLEC2, Leu-14, molécule d'adhésion
                               cellulaire du lymphocyte B, BL-CAM)], Mus musculus fragment Fv
                               d'anticorps monoclonal stabilisé par un pont disulfure avec le
                               domaine VH de la chaîne lourde fusionné à la forme tronquée PE38
                               de l'exotoxine A de Pseudomonas aeruginosa (VH-PE38), lié par un
                               pont disulfure au domaine variable kappa (V-KAPPA)];
                               VH-PE38 (1-476) comprenant le domaine VH (1-123) [méthionyl -
                               Mus musculus VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-
                               123)] fusionné à un 7-mer linker (124-130) et au fragment PE38 de
                               l'exotoxine A de Pseudomonas aeruginosa (ETA) (131-476)
                               [fragment précurseur 277-638 avec del 389-405>N (131-476),
                               comprenant domaine II (131-243) dont le site de clivage
                               protéolytique par la furine (152-164), domaine Ib (244-267), domaine
                               III (268-476)], (45-101')- disulfure avec V-KAPPA (1'-108')
                               [méthionyl- Mus musculus V-KAPPA (IGHKV10-96*01 -IGKJ1*01)
                               [6.3.9] (2'-108')]

 moxetumomab pasudotox         fragmento Fv de inmunoglobulina fusionado con toxina de
                               Pseudomonas, anti-[Homo sapiens CD22 (lectina de tipo
                               inmunoglobulina 2 que se une al ácido siálico, Siglec-2, SIGLEC2,
                               Leu-14, molécula de adhesión celular del linfocito B, BL-CAM)], Mus
                               musculus fragmento Fv de anticuerpo monoclonal estabilizado por
                               un puente disulfuro con el dominio VH de la cadena pesada
                               fusionado a la forma truncada PE38 de la exotoxina A de
                               Pseudomonas aeruginosa (VH-PE38), unida por un puente disulfuro
                               al dominio variable kappa (V-KAPPA)];
                               VH-PE38 (1-476) que comprende el dominio VH (1-123) [metionil -
                               Mus musculus VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-
                               123)] fusionado a un heptámero de unión(124-130) y al fragmento
                               PE38 de la exotoxina A de Pseudomonas aeruginosa (ETA) (131-
                               476) [fragmento precursor 277-638 con del 389-405>N (131-476),
                               comprende el dominio II (131-243) con el sitio de ruptura proteolítica
                               por la furina (152-164), dominio Ib (244-267), dominio III (268-476)],
                               (45-101')- disulfuro con V-KAPPA (1'-108') [metionil- Mus musculus
                               V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (2'-108')]




274
WHO Drug Information, Vol. 24, No. 3, 2010                                                             Recommended INN: List 64




                                             VH-PE38 chain / Chaîne VH-PE38 / Cadena VH-PE38
                                             MEVQLVESGG GLVKPGGSLK LSCAASGFAF SIYDMSWVRQ                        TPEKCLEWVA        50
                                             YISSGGGTTY YPDTVKGRFT ISRDNAKNTL YLQMSSLKSE                        DTAMYYCARH       100
                                             SGYGTHWGVL FAYWGQGTLV TVSAKASGGP EGGSLAALTA                        HQACHLPLET       150
                                             FTRHRQPRGW EQLEQCGYPV QRLVALYLAA RLSWNQVDQV                        IRNALASPGS       200
                                             GGDLGEAIRE QPEQARLALT LAAAESERFV RQGTGNDEAG                        AANGPADSGD       250
                                             ALLERNYPTG AEFLGDGGDV SFSTRGTQNW TVERLLQAHR                        QLEERGYVFV       300
                                             GYHGTFLEAA QSIVFGGVRA RSQDLDAIWR GFYIAGDPAL                        AYGYAQDQEP       350
                                             DARGRIRNGA LLRVYVPRSS LPGFYRTSLT LAAPEAAGEV                        ERLIGHPLPL       400
                                             RLDAITGPEE EGGRLETILG WPLAERTVVI PSAIPTDPRN                        VGGDLDPSSI       450
                                             PDKEQAISAL PDYASQPGKP PREDLK                                                        476

                                             V-KAPPA chain / Chaîne V-KAPPA / Cadena V-KAPPA
                                             MDIQMTQTTS SLSASLGDRV TISCRASQDI SNYLNWYQQK PDGTVKLLIY 50
                                             YTSILHSGVP SRFSGSGSGT DYSLTISNLE QEDFATYFCQ QGNTLPWTFG 100
                                             CGTKLEIK                                               108

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 23-97 144-166
                                             Intra-L 24'-89'
                                             Inter-H-L 45-101'




 narlaprevirum
 narlaprevir                                 (1R,2S,5S)-N-[(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-
                                             3-{(2S)-3,3-dimethyl-2-[({1-[(2-methylpropane-
                                             2-sulfonyl)methyl]cyclohexyl}carbamoyl)amino]butanoyl}-
                                             6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

 narlaprévir                                 (1R,2S,5S)-N-[(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-
                                             3-{(2S)-3,3-diméthyl-2-[({1-[(2-méthylpropane-
                                             2-sulfonyl)méthyl]cyclohexyl}carbamoyl)amino]butanoyl}-
                                             6,6-diméthyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

 narlaprevir                                 (1R,2S,5S)-N-[(3S)-1-(ciclopropilamino)-1,2-dioxoheptan-3-yl]-
                                             3-{(2S)-3,3-dimetil-2-[({1-[(2-metilpropane-
                                             2-sulfonil)metil]ciclohexil}carbamoil)amino]butanoil}-6,6-dimetil-
                                             3-azabiciclo[3.1.0]hexane-2-carboxamida

                                             C36H61N5O7S
                                                                                   CH3                CH3
                                                                         H3C            H
                                                                                    CH3                CH3
                                                      O O               O
                                                                                     H                        O
                                             H3C       S                                 N          H                   H
                                                                    N        N                     HN                   N
                                                                    H        H
                                              H3C CH3                                O       H
                                                                                                  O     H         O

                                                                                                                  CH3



 omadacyclinum
 omadacycline                                (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-9-{[(2,2-
                                             dimethylpropyl)amino]methyl}-3,10,12,12a-tetrahydroxy-1,11-dioxo-
                                             1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

 omadacycline                                (4S,4aS,5aR,12aS)-4,7-bis(diméthylamino)-9-{[(2,2-
                                             diméthylpropyl)amino]méthyl}-3,10,12,12a-tétrahydroxy-1,11-dioxo-
                                             1,4,4a,5,5a,6,11,12a-octahydrotétracène-2-carboxamide

 omadaciclina                                (4S,4aS,5aR,12aS)-4,7-bis(dimetilamino)-9-{[(2,2-
                                             dimetilpropil)amino]metil}-3,10,12,12a-tetrahidroxi-1,11-dioxo-
                                             1,4,4a,5,5a,6,11,12a-octahidrotetraceno-2-carboxamida




                                                                                                                                           275
Recommended INN: List 64                                       WHO Drug Information, Vol. 24, No. 3, 2010


                           C29H40N4O7

                                                      OH        O        OH O         O
                                                                           OH
                           H3 C
                                         N                                                  NH2
                                         H
                            H3C   CH3
                                                                                      OH
                                                                    H         H
                                                      N                        H N    CH3
                                             H3C           CH3
                                                                              H3C



 omecamtivum mecarbilum
 omecamtiv mecarbil        methyl 4-[(2-fluoro-3-{[N-(6-methylpyridin-
                           3-yl)carbamoyl]amino}phenyl)methyl]piperazine-1-carboxylate

 omécamtiv mécarbil        4-[(2-fluoro-3-{[N-(6-méthylpyridin-
                           3-yl)carbamoyl]amino}phényl)méthyl]pipérazine-1-carboxylate de
                           méthyle

 omecamtiv mecarbilo       4-[(2-fluoro-3-{[N-(6-metilpiridin-
                           3-il)carbamoil]amino}fenil)metil]piperazina-1-carboxilato de metilo

                           C20H24FN5O3

                                                                                      O
                           H3 C     N                                                           CH3
                                                 O                                N         O
                                                                              N
                                             N        N
                                             H        H
                                                                F



 plinabulinum
 plinabulin                (3Z,6Z)-3-benzylidene-6-{[5-(tert-butyl)-1H-imidazol-
                           4-yl]methylidene}piperazine-2,5-dione

 plinabuline               (3Z,6Z)-3-benzylidène-6-{[5-(tert-butyl)-1H-imidazol-
                           4-yl]méthylidène}pipérazine-2,5-dione

 plinabulina               (3Z,6Z)-3-bencilideno-6-{[5-(terc-butil)-1H-imidazol-
                           4-il]metilideno}piperazina-2,5-diona

                           C19H20N4O2

                                                          H3C        CH3
                                             O
                                                                        CH3
                                        HN
                                                                    NH
                                                 NH        N

                                             O



 pridopidinum
 pridopidine               4-[3-(methanesulfonyl)phenyl]-1-propylpiperidine

 pridopidine               4-[3-(méthanesulfonyl)phényl]-1-propylpipéridine

 pridopidina               4-[3-(metanosulfonil)fenil]-1-propilpiperidina



276
WHO Drug Information, Vol. 24, No. 3, 2010                                                        Recommended INN: List 64


                                             C15H23NO2S



                                             H 3C
                                                   S
                                                  O O                           N
                                                                                            CH3


 raseglurantum
 raseglurant                                 2-[2-(3-fluorophenyl)ethynyl]-4,6-dimethylpyridin-3-amine

 raséglurant                                 2-[2-(3-fluorophényl)éthynyl]-4,6-diméthylpyridin-3-amine

 raseglurant                                 2-[2-(3-fluorofenil)etinil]-4,6-dimetilpiridin-3-amina

                                             C15H13FN3

                                                      CH3

                                                            N

                                             H3C
                                                                                        F
                                                      NH2




 remimazolamum
 remimazolam                                 methyl 3-{(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-
                                             a][1,4]benzodiazepin-4-yl}propanoate

 rémimazolam                                 3-{(4S)-8-bromo-1-méthyl-6-(pyridin-2-yl)-4H-imidazo[1,2-
                                             a][1,4]benzodiazépin-4-yl}propanoate de méthyle

 remimazolam                                 3-{(4S)-8-bromo-1-metil-6-(piridin-2-il)-4H-imidazo[1,2-
                                             a][1,4]benzodiazepin-4-il}propanoato de metilo

                                             C21H19BrN4O2

                                                     H3 C
                                                                        N           O
                                                                N
                                                                                            CH3
                                                                                        O
                                                                            H
                                             Br                     N

                                                        N




 resminostatum
 resminostat                                 (2E)-3-[1-({4-[(dimethylamino)methyl]phenyl}sulfonyl)-1H-pyrrol-3-yl]-
                                             N-hydroxyprop-2-enamide

 resminostat                                 (2E)-3-[1-({4-[(diméthylamino)méthyl]phényl}sulfonyl)-1H-pyrrol-3-yl]-
                                             N-hydroxyprop-2-énamide

 resminostat                                 (2E)-3-[1-({4-[(dimetilamino)metil]fenil}sulfonil)-1H-pirrol-3-il]-
                                             N-hidroxiprop-2-enamida




                                                                                                                       277
Recommended INN: List 64                                      WHO Drug Information, Vol. 24, No. 3, 2010


                           C16H19N3O4S

                                                 O O                         O
                                                     S                               OH
                                    CH3                   N                      N
                                                                                 H
                                    N
                           H3C


 revamilastum
 revamilast                3,5-dichloro-4-{[6-(difluoromethoxy)[1]benzofuro[3,2-c]pyridine-
                           9-yl]carboxamido}pyridine 1-oxide

 révamilast                1-oxyde de 3,5-dichloro-4-{[6-(difluorométhoxy)[1]benzofuro[3,2-
                           c]pyridine-9-yl]carboxamido}pyridine

 revamilast                1-óxido de 3,5-dicloro-4-[6-(difluorometoxi)[1]benzofuro[3,2-
                           c]piridina-9-carboxamido]piridina

                           C18H9Cl2F2N3O4

                           F        O
                                                               Cl
                                                     H
                                F                    N
                                    O
                                                 O                  N
                                                     Cl                 O
                                           N


 rintatolimodum
 rintatolimod              poly[5')-inosinylyl-(3'→] duplex with poly[dodecakis[3')-cytidylyl-
                           (5'→]3')-uridylyl-(5'→]

 rintatolimod              poly[5')-inosinylyl-(3'→] duplex avec poly[dodécakis[3')-cytidylyl-
                           (5'→]3')-uridylyl-(5'→]

 rintatolimod              poli[5')-inosinilil-(3'→] dúplex con poli[dodecakis[3')-citidilil-(5'→]3')-
                           uridilil-(5'→]

                           [[C10H11N4O7P]13]n . [[C9H12N3O7P]12[C9H11N2O8P]]n


                               (3'-5') H
                                           . I. . . . . . .I . . . . I.
                                           I    I I I I I    I I I I                          OH
                           (5'-3') HO      U C   C C C           C C        C C C     C C C   H
                                                                                              n



 secukinumabum #
 secukinumab               immunoglobulin G1-kappa, anti-[Homo sapiens interleukin 17A
                           (IL17A, IL-17A)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-457) [Homo sapiens VH (IGHV3-7*01
                           (92.90%) -(IGHD)-IGHJ2*01) [8.8.20] (1-127) -IGHG1*03 (128-457)],
                           (230-215')-disulfide with kappa light chain (1'-215') [Homo sapiens
                           V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ2*02) [7.3.9] (1'-108') -
                           IGKC*01 (109'-215')]; (269-236'':239-239'')-bisdisulfide dimer

 sécukinumab               immunoglobuline G1-kappa, anti-[Homo sapiens interleukine 17A
                           (IL17A, IL-17A)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-457) [Homo sapiens VH (IGHV3-7*01
                           (92.90%) -(IGHD)-IGHJ2*01) [8.8.20] (1-127) -IGHG1*03 (128-457)],
                           (230-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo
                           sapiens V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ2*01) [7.3.9] (1'-
                           108') -IGKC*01 (109'-215')]; dimère (236-236'':239-239'')-bisdisulfure



278
WHO Drug Information, Vol. 24, No. 3, 2010                                                           Recommended INN: List 64


 secukinumab                                 inmunoglobulina G1-kappa, anti-[Homo sapiens IL17A (interleukina
                                             17A, IL-17A)], anticuerpo monoclonal de Homo sapiens;
                                             cadena pesada gamma1 (1-457) [Homo sapiens VH (IGHV3-7*01
                                             (92.90%) -(IGHD)-IGHJ2*01) [8.8.20] (1-127) -IGHG1*03 (128-457)],
                                             (230-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
                                             sapiens V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ2*01) [7.3.9] (1'-
                                             108') -IGKC*01 (109'-215')]; dímero bisdisulfuro-(236-236'':239-239'')

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  NYWMNWVRQA       PGKGLEWVAA        50
                                             INQDGSEKYY VGSVKGRFTI SRDNAKNSLY                  LQMNSLRVED       TAVYYCVRDY       100
                                             YDILTDYYIH YWYFDLWGRG TLVTVSSAST                  KGPSVFPLAP       SSKSTSGGTA       150
                                             ALGCLVKDYF PEPVTVSWNS GALTSGVHTF                  PAVLQSSGLY       SLSSVVTVPS       200
                                             SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC                  DKTHTCPPCP       APELLGGPSV       250
                                             FLFPPKPKDT LMISRTPEVT CVVVDVSHED                  PEVKFNWYVD       GVEVHNAKTK       300
                                             PREEQYNSTY RVVSVLTVLH QDWLNGKEYK                  CKVSNKALPA       PIEKTISKAK       350
                                             GQPREPQVYT LPPSREEMTK NQVSLTCLVK                  GFYPSDIAVE       WESNGQPENN       400
                                             YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG                  NVFSCSVMHE       ALHNHYTQKS       450
                                             LSLSPGK                                                                             457

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVLTQSPGT LSLSPGERAT LSCRASQSVS                  SSYLAWYQQK       PGQAPRLLIY 50
                                             GASSRATGIP DRFSGSGSGT DFTLTISRLE                  PEDFAVYYCQ       QYGSSPCTFG 100
                                             QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                             VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                             GLSSPVTKSF NRGEC                                                              215

                                             Disulfide bridges location / Position des ponts disulfure /Posiciones de los puentes disulfuro
                                             Intra-H 22-96        154-210       271-331  377-435
                                                       22''-96'' 154''-210'' 271''-331'' 377''-435''
                                             Intra-L 23'-89'      135'-195'
                                                      23'''-89''' 135'''-195'''
                                             Inter-H-L 230-215' 230''-215'''
                                             Inter-H-H 236-236'' 239-239''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             307, 307''




 selexipagum
 selexipag                                   2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-
                                             N-(methanesulfonyl)acetamide

 sélexipag                                   2-{4-[(5,6-diphénylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-
                                             N-(méthanesulfonyl)acétamide

 selexipag                                   2-{4-[(5,6-difenilpirazin-2-il)(propan-2-il)amino]butoxi}-
                                             N-(metanosulfonil)acetamida

                                             C26H32N4O4S

                                                             H3C        CH3
                                                                                                   H
                                                            N       N                              N       CH3
                                                                                       O               S
                                                                                               O     O O
                                                            N




 sotaterceptum #
 sotatercept                                 fusion protein for immune applications (FPIA) comprising ACVR2A
                                             (activin receptor type 2A, activin receptor type IIA) fragment fused
                                             with immunoglobulin G1 Fc fragment, and binding activin, a member
                                             of the TGF beta family;
                                             ACVR2A, 21-135 precursor fragment (1-115) -threonyl-triglycyl linker
                                             (116-119) -gamma1 chain H-CH2-CH3 fragment (120-344) [Homo
                                             sapiens IGHG1*03 hinge (120-127), CH2, A115>V (128-237), CH3
                                             (238-344)]; (123-123':126-126')-bisdisulfide dimer


                                                                                                                                        279
Recommended INN: List 64                                    WHO Drug Information, Vol. 24, No. 3, 2010


 sotatercept               protéine de fusion pour applications immunitaires (FPIA) comprenant
                           un fragment d'ACVR2A (récepteur type 2A de l'activine, récepteur
                           type IIA de l'activine) fusionné au fragment Fc de l'immunoglobuline
                           G1, et liant l'activine, un membre de la famille du TGF bêta;
                           fragment précurseur 21-135 de ACVR2A (1-115) -linker thréonyl-
                           triglycyl (116-119) -fragment H-CH2-CH3 de chaîne gamma1 (120-
                           344) [Homo sapiens IGHG1*03 charnière (120-127), CH2, A115>V
                           (128-237), CH3 (238-344)]; dimère (123-123':126-126')-bisdisulfure

 sotatercept               proteína de fusión para aplicaciones inmunitarias (FPIA) que
                           comprende un fragmento de ACVR2A (receptor tipo 2A de la
                           activina, receptor tipo IIA de la activina) fusionado al fragmento Fc
                           de la inmunoglobulina G1, y que capta la activina, un miembro de la
                           familia del TGF beta;
                           fragmento precursor 21-135 de ACVR2A (1-115)-conector treonil-
                           triglicil (116-119) -fragmento H-CH2-CH3 de cadena gamma1 (120-
                           344) [Homo sapiens IGHG1*03 bisagra(120-127), CH2, A115>V
                           (128-237), CH3 (238-344)]; dímero (123-123':126-126')-bisdisulfuro

                           C3448H5264N920O1058S42

                           Fused chain / chaine fusionnée / cadena fusionada
                           ILGRSETQEC LFFNANWEKD RTNQTGVEPC YGDKDKRRHC                        FATWKNISGS        50
                           IEIVKQGCWL DDINCYDRTD CVEKKDSPEV YFCCCEGNMC                        NEKFSYFPEM       100
                           EVTQPTSNPV TPKPPTGGGT HTCPPCPAPE LLGGPSVFLF                        PPKPKDTLMI       150
                           SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE                        EQYNSTYRVV       200
                           SVLTVLHQDW LNGKEYKCKV SNKALPVPIE KTISKAKGQP                        REPQVYTLPP       250
                           SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT                        TPPVLDSDGS       300
                           FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL                        SPGK             344

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-chain 10-40 30-58        65-84 71-83 85-90 158-218 264-322
                                        10'-40' 30'-58' 65'-84' 71'-83' 85'-90' 158'-218' 264'-322'
                           Inter-chains 123-123' 126-126'

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           23, 46, 194, 23', 46', 194'



 suvizumabum #
 suvizumab                 immunoglobulin G1-kappa, anti-[human immunodeficiency virus type
                           1 (HIV-1) envelope glycoprotein gp120 third variable loop V3],
                           humanized monoclonal antibody;
                           gamma1 heavy chain (1-448) [humanized VH (Homo sapiens
                           IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo
                           sapiens IGHG1*01 (119-448)], (221-220')-disulfide with kappa light
                           chain (1'-220') [humanized V-KAPPA (Homo sapiens IGKV4-1*01
                           (77.20%) -IGKJ1*01) [12.3.9] (1'-113') -Homo sapiens IGKC*01
                           (114'-220')]; (227-227":230-230")-bisdisulfide dimer

 suvizumab                 immunoglobuline G1-kappa, anti-[troisième boucle variable V3 de la
                           glycoprotéine d'enveloppe gp120 du virus type 1 de
                           l'immunodéficience humaine (VIH-1)], anticorps monoclonal
                           humanisé;
                           chaîne lourde gamma1 (1-448) [VH humanisé (Homo sapiens
                           IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo
                           sapiens IGHG1*01 (119-448)], (221-220')-disulfure avec la chaîne
                           légère kappa (1'-220') [V-KAPPA humanisé (Homo sapiens IGKV4-
                           1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') -Homo sapiens IGKC*01
                           (114'-220')]; dimère (227-227":230-230")-bisdisulfure




280
WHO Drug Information, Vol. 24, No. 3, 2010                                                           Recommended INN: List 64


 suvizumab                                   inmunoglobulina G1-kappa, anti-[tercer bucle variable V3 de la
                                             glicoproteína de la envoltura gp120 del virus tipo 1 de la
                                             inmunodeficiencia humana (VIH-1)], anticuerpo monoclonal
                                             humanizado;
                                             cadena pesada gamma1 (1-448) [VH humanizado(Homo sapiens
                                             IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -Homo
                                             sapiens IGHG1*01 (119-448)], (221-220')-disulfuro con la cadena
                                             ligera kappa (1'-220') [V-KAPPA humanizada (Homo sapiens IGKV4-
                                             1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') -Homo sapiens IGKC*01
                                             (114'-220')]; dímero bisdisulfuro-(227-227":230-230")

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  NSWIGWFRQA       PGQGLEWIGD        50
                                             IYPGGGYTNY NEIFKGKATM TADTSTNTAY                  MELSSLRSED       TAVYYCSRGI       100
                                             PGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                             FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                             CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                                             TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                                             YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                             TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                             SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK         448

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQRPDS LSASVGDRVT MSCKSSQSLL                  NSGDQKNYLT       WYQQKPGQPP 50
                                             KLLIYWASTG ESGVPDRFSG SGSGTDFTFT                  ISSLQPEDIA       TYYCQNDYSY 100
                                             PWTFGQGTKV EIKRTVAAPS VFIFPPSDEQ                  LKSGTASVVC       LLNNFYPREA 150
                                             KVQWKVDNAL QSGNSQESVT EQDSKDSTYS                  LSSTLTLSKA       DYEKHKVYAC 200
                                             EVTHQGLSSP VTKSFNRGEC                                                         220

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 21-96        145-201       262-322  368-426
                                                       21''-96'' 145''-201'' 262''-322'' 368''-426''
                                             Intra-L 23'-94'      140'-200'
                                                      23'''-94''' 140'''-200'''
                                             Inter-H-L 221-220' 221''-220'''
                                             Inter-H-H 227-227'' 230-230''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             298, 298''




 tafoxiparinum natricum
 tafoxiparin sodium                          sodium salt of a low molecular mass heparin that is obtained by
                                             periodate oxidative depolymerization of heparin from porcine
                                             intestinal mucosa followed alkaline β-elimination and reduction of the
                                             products; the majority of the components have a 2-deoxy-6-O-sulfo-
                                             2-(sulfoamino)-α-D-glucopyranosyl structure at the non-reducing end
                                             and a (hydroxymethyl)allyl 2-deoxy-6-O-sulfo-2-(sulfoamino)-
                                             α-D-glucopyranoside structure at the reducing end of their chain; the
                                             average molecular mass is approximately 6000 Daltons and 80% of
                                             the components ranging between 2000 and 10000 Daltons; the
                                             degree of sulfatation is of 2 to 2.5 per disaccharidic unit

 tafoxiparine sodique                        sel de sodium d'héparine de basse masse moléculaire obtenue par
                                             dépolymérisation oxydative, à l'aide de periodate, d'héparine de
                                             muqueuse intestinale de porc, suivie d'une β-élimination alcaline
                                             puis d'une réduction des produits. La majorité des composants
                                             présentent une structure 2-déoxy-6-O-sulfo-2-(sulfoamino)-
                                             α-D-glucopyranosyle à l'extrémité non réductrice et une structure
                                             2-déoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranoside de
                                             (hydroxyméthyl)allyle à l'extrémité réductrice de leur chaîne; les
                                             masses moléculaires relatives des constituants ont une moyenne
                                             voisine de 6000 Daltons et celles de 80% des constituants sont
                                             comprises entre 2000 et 10000; le degré de sulfatation est compris
                                             entre 2 et 2,5 par unité disaccharide




                                                                                                                                       281
Recommended INN: List 64                                  WHO Drug Information, Vol. 24, No. 3, 2010


 tafoxiparina sódica       sal sódica de la heparina de baja masa molecular obtenida de
                           mucosa intestinal de cerdo por despolimerización oxidativa mediante
                           un proceso controlado en el que se utiliza periodato, siguido de una
                           β-eliminación alcalina y de una reducción de los productos.
                           La mayoría de los componentes presentan la estructura 2-desoxi-
                           6-O-sulfo-2-(sulfoamino)-α-D-glucopiranosilo en el extremo no
                           reductor y la estructura 2-desoxi-6-O-sulfo-2-(sulfoamino)-
                           α-D-glucopiranosido de (hidroximetilo)alilo en el extremo reductor de
                           su cadena ; la masa molecular relativa media es de
                           aproximadamente 6000 daltons y la masa molecular relativa media
                           de 80 % de los componentes está comprendida entre 2000 y 10000,
                           el grado de sulfatación oscila entre 2 y 2,5 por unidad de disacárido

 tenifatecanum
 tenifatecan               (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-
                           1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl (2R)-2,5,7,8-
                           tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-
                           2H-chromen-6-yl butanedioate

 ténifatécan               butanedioate de (4S)-4,11-diéthyl-4-hydroxy-3,14-dioxo-3,4,12,14-
                           tétrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléin-9-yle et de
                           (2R)-2,5,7,8-tétraméthyl-2-[(4R,8R)-4,8,12-triméthyltridécyl]-
                           3,4-dihydro-2H-chromén-6-yle

 tenifatecán               butanodioato de (4S)-4,11-dietil-4-hidroxi-3,14-dioxo-3,4,12,14-
                           tetrahidro-1H-pirano[3',4':6,7]indolizino[1,2-b]quinolin-9-ilo y
                           (2R)-2,5,7,8-tetrametil-2-[(4R,8R)-4,8,12-trimetiltridecil]-3,4-dihidro-
                           2H-cromen-6-ilo

                           C55H72N2O9

                                                  CH3
                                                                                             CH3
                               H 3C           O
                                                           H   CH3       H   CH3        CH3
                           H3C                                           O
                                                           CH3

                                 O            CH3                    N             O
                                                      O
                                 O                                                      O
                                                                 N           HO        CH3
                                                      O


 tideglusibum
 tideglusib                4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione

 tidéglusib                4-benzyl-2-(naphtalén-1-yl)-1,2,4-thiadiazolidine-3,5-dione

 tideglusib                4-bencil-2-(naftalen-1-il)-1,2,4-tiadiazolidina-3,5-diona

                           C19H14N2SO2



                                          O

                                      N       N
                                      S
                                                  O




282
WHO Drug Information, Vol. 24, No. 3, 2010                                                      Recommended INN: List 64


 tivozanibum
 tivozanib                                   1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-
                                             1,2-oxazol-3-yl)urea

 tivozanib                                   1-{2-chloro-4-[(6,7-diméthoxyquinoléin-4-yl)oxy]phényl}-3-(5-méthyl-
                                             1,2-oxazol-3-yl)urée

 tivozanib                                   1-{2-cloro-4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-3-(5-metil-
                                             1,2-oxazol-3-il)urea

                                             C22H19ClN4O5

                                             H3CO                   N


                                             H3CO
                                                                                                CH3
                                                                    O
                                                                                    O
                                                                                                O
                                                                                N       N   N
                                                                                H       H
                                                                         Cl


 tonapofyllinum
 tonapofylline                               3-{4-[2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-
                                             8-yl]bicyclo[2.2.2]octan-1-yl}propanoic acid

 tonapofylline                               acide 3-{4-[2,6-dioxo-1,3-dipropyl-2,3,6,7-tétrahydro-1H-purin-
                                             8-yl]bicyclo[2.2.2]octan-1-yl}propanoïque

 tonapofilina                                ácido 3-{4-[2,6-dioxo-1,3-dipropil-2,3,6,7-tetrahidro-1H-purin-
                                             8-il]biciclo[2.2.2]octan-1-il}propanoico

                                             C22H32N4O4

                                                                O
                                             H3C                        H
                                                                        N                   CO2H
                                                           N

                                                       O        N       N

                                                                        CH3


 topiroxostatum
 topiroxostat                                4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile

 topiroxostat                                4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile

 topiroxostat                                4-[5-(piridin-4-il)-1H-1,2,4-triazol-3-il]piridina-2-carbonitrilo

                                             C13H8N6

                                                 CN

                                             N                              N
                                                            N

                                                           N NH




                                                                                                                     283
Recommended INN: List 64                                    WHO Drug Information, Vol. 24, No. 3, 2010


 tralokinumabum #
 tralokinumab              immunoglobulin G4-lambda, anti-[Homo sapiens IL13 (interleukin 13,
                           IL-13)], Homo sapiens monoclonal antibody;
                           gamma4 heavy chain (1-449) [Homo sapiens VH (IGHV1-18*01
                           (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01 (123-449)],
                           (136-213')-disulfide with lambda light chain (1'-214') [Homo sapiens
                           V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-108') -
                           IGLC2*01 (109'-214')]; (228-228'':231-231'')-bisdisulfide dimer

 tralokinumab              immunoglobuline G4-lambda, anti-[Homo sapiens IL13 (interleukine
                           13, IL-13)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma4 (1-449) [Homo sapiens VH (IGHV1-18*01
                           (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01(123-449)],
                           (136-213')-disulfure avec la chaîne légère lambda (1'-214') [Homo
                           sapiens V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-
                           108') -IGLC2*01 (109'-214')]; dimère (228-228'':231-231'')-
                           bisdisulfure

 tralokinumab              inmunoglobulina G4-lambda, anti-[IL13 (interleukina 13, IL-13) de
                           Homo sapiens], anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma4 (1-449) [Homo sapiens VH (IGHV1-18*01
                           (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01(123-449)],
                           (136-213')-disulfuro con la cadena ligera lambda (1'-214') [Homo
                           sapiens V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-
                           108') -IGLC2*01 (109'-214')]; dímero (228-228'':231-231'')-
                           bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  NYGLSWVRQA       PGQGLEWMGW        50
                           ISANNGDTNY GQEFQGRVTM TTDTSTSTAY                  MELRSLRSDD       TAVYYCARDS       100
                           SSSWARWFFD LWGRGTLVTV SSASTKGPSV                  FPLAPCSRST       SESTAALGCL       150
                           VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                  SSGLYSLSSV       VTVPSSSLGT       200
                           KTYTCNVDHK PSNTKVDKRV ESKYGPPCPS                  CPAPEFLGGP       SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY                  VDGVEVHNAK       TKPREEQFNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL                  PSSIEKTISK       AKGQPREPQV       350
                           YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                           DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM                  HEALHNHYTQ       KSLSLSLGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           SYVLTQPPSV SVAPGKTARI TCGGNIIGSK                  LVHWYQQKPG       QAPVLVIYDD 50
                           GDRPSGIPER FSGSNSGNTA TLTISRVEAG                  DEADYYCQVW       DTGSDPVVFG 100
                           GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN                  KATLVCLISD       FYPGAVTVAW 150
                           KADSSPVKAG VETTTPSKQS NNKYAASSYL                  SLTPEQWKSH       RSYSCQVTHE 200
                           GSTVEKTVAP TECS                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        149-205 263-323        369-427
                                    22''-96'' 149''-205'' 263''-323'' 369''-427''
                           Intra-L 22'-87'       136'-195'
                                    22'''-87''' 136'''-195'''
                           Inter-H-L 136-213' 136''-213'''
                           Inter-H-H 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''


 varlitinibum
                            4                                                                   6
 varlitinib                N -{3-chloro-4-[(1,3-thiazol-2-yl)methoxy]phenyl}-N -[(4R)-4-methyl-
                           4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine
                            4                                                                   6
 varlitinib                N -{3-chloro-4-[(1,3-thiazol-2-yl)méthoxy]phényl}-N -[(4R)-4-méthyl-
                           4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine
                            4                                                        6
 varlitinib                N -{3-cloro-4-[(1,3-tiazol-2-il)metoxi]fenil}-N -[(4R)-4-metil-
                           4,5-dihidro-1,3-oxazol-2-il]quinazolina-4,6-diamina




284
WHO Drug Information, Vol. 24, No. 3, 2010                                                  Recommended INN: List 64


                                             C22H19CIN6O2S

                                                                            N
                                             H3C             O
                                                H                               N
                                                       N         N
                                                                 H
                                                                           HN        Cl

                                                                                                 N
                                                                                     O
                                                                                             S

 veliparibum
 veliparib                                   2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide

 véliparib                                   2-[(2R)-2-méthylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide

 veliparib                                   2-[(2R)-2-metilpirrolidin-2-il]-1H-benzoimidazol-4-carboxamida

                                             C13H16N4O

                                                                 O   NH2

                                                    NH       N


                                                    CH3 N
                                                        H

 verucerfontum
 verucerfont                                 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-
                                             1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine

 vérucerfont                                 3-(4-méthoxy-2-méthylphényl)-2,5-diméthyl-N-[(1S)-1-(3-méthyl-
                                             1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine

 verucerfont                                 2,5-dimetil-3-(2-metilfenil-4-metoxi)-N-[(1S)-1-(3-metil-
                                             1,2,4-oxadiazol-5-il)propil]pirazolo[1,5-a]pirimidin-7-amina

                                             C22H26N6O2

                                                                             CH3
                                                                      N
                                                                 H
                                                                 N   N
                                                H3 C                                      OCH3
                                                     N           H         N H C
                                                                              3
                                                             O
                                             H3C         N           CH3


 volasertibum
 volasertib                                  N-{trans-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}-
                                             4-{[(7R)-7-ethyl-5-methyl-6-oxo-8-(propan-2-yl)-
                                             5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxybenzamide

 volasertib                                  N-{trans-4-[4-(cyclopropylméthyl)pipérazin-1-yl]cyclohexyl}-
                                             4-{[(7R)-7-éthyl-5-méthyl-6-oxo-8-(propan-2-yl)-
                                             5,6,7,8-tétrahydroptéridin-2-yl]amino}-3-méthoxybenzamide

 volasertib                                  N-{trans-4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}-4-{[(7R)-7-etil-
                                             5-metil-6-oxo-8-(propan-2-il)-5,6,7,8-tetrahidropteridin-2-il]amino}-
                                             3-metoxibenzamida



                                                                                                                      285
Recommended INN: List 64                                  WHO Drug Information, Vol. 24, No. 3, 2010


                           C34H50N8O3

                                 H3C        CH3
                           H3C                        H
                                       N      N       N
                                 H
                                                                       H
                                                  N                    N
                                 O     N              O
                                       CH3            CH3         O
                                                                                    N
                                                                                         N


 vonicogum alfa #
 vonicog alfa              [618-threonine,709-aspartic acid]von Willebrand factor Homo
                           sapiens (1381A>T,1472H>D variant)

 vonicog alfa              [618-thréonine,709-acide aspartique]facteur de von Willebrand
                           Homo sapiens (variant 1381A>T,1472H>D)

 vonicog alfa              [618-treonina,709-ácido aspatico]factor de von Willebrand Homo
                           sapiens (variante 1381A>T,1472H>D)

                           C9712H15373N2737O3032S210

                           SLSCRPPMVK      LVCPADNLRA     EGLECTKTCQ   NYDLECMSMG   CVSGCLCPPG     50
                           MVRHENRCVA      LERCPCFHQG     KEYAPGETVK   IGCNTCVCRD   RKWNCTDHVC    100
                           DATCSTIGMA      HYLTFDGLKY     LFPGECQYVL   VQDYCGSNPG   TFRILVGNKG    150
                           CSHPSVKCKK      RVTILVEGGE     IELFDGEVNV   KRPMKDETHF   EVVESGRYII    200
                           LLLGKALSVV      WDRHLSISVV     LKQTYQEKVC   GLCGNFDGIQ   NNDLTSSNLQ    250
                           VEEDPVDFGN      SWKVSSQCAD     TRKVPLDSSP   ATCHNNIMKQ   TMVDSSCRIL    300
                           TSDVFQDCNK      LVDPEPYLDV     CIYDTCSCES   IGDCACFCDT   IAAYAHVCAQ    350
                           HGKVVTWRTA      TLCPQSCEER     NLRENGYECE   WRYNSCAPAC   QVTCQHPEPL    400
                           ACPVQCVEGC      HAHCPPGKIL     DELLQTCVDP   EDCPVCEVAG   RRFASGKKVT    450
                           LNPSDPEHCQ      ICHCDVVNLT     CEACQEPGGL   VVPPTDAPVS   PTTLYVEDIS    500
                           EPPLHDFYCS      RLLDLVFLLD     GSSRLSEAEF   EVLKAFVVDM   MERLRISQKW    550
                           VRVAVVEYHD      GSHAYIGLKD     RKRPSELRRI   ASQVKYAGSQ   VASTSEVLKY    600
                           TLFQIFSKID      RPEASRITLL     LMASQEPQRM   SRNFVRYVQG   LKKKKVIVIP    650
                           VGIGPHANLK      QIRLIEKQAP     ENKAFVLSSV   DELEQQRDEI   VSYLCDLAPE    700
                           APPPTLPPDM      AQVTVGPGLL     GVSTLGPKRN   SMVLDVAFVL   EGSDKIGEAD    750
                           FNRSKEFMEE      VIQRMDVGQD     SIHVTVLQYS   YMVTVEYPFS   EAQSKGDILQ    800
                           RVREIRYQGG      NRTNTGLALR     YLSDHSFLVS   QGDREQAPNL   VYMVTGNPAS    850
                           DEIKRLPGDI      QVVPIGVGPN     ANVQELERIG   WPNAPILIQD   FETLPREAPD    900
                           LVLQRCCSGE      GLQIPTLSPA     PDCSQPLDVI   LLLDGSSSFP   ASYFDEMKSF    950
                           AKAFISKANI      GPRLTQVSVL     QYGSITTIDV   PWNVVPEKAH   LLSLVDVMQR   1000
                           EGGPSQIGDA      LGFAVRYLTS     EMHGARPGAS   KAVVILVTDV   SVDSVDAAAD   1050
                           AARSNRVTVF      PIGIGDRYDA     AQLRILAGPA   GDSNVVKLQR   IEDLPTMVTL   1100
                           GNSFLHKLCS      GFVRICMDED     GNEKRPGDVW   TLPDQCHTVT   CQPDGQTLLK   1150
                           SHRVNCDRGL      RPSCPNSQSP     VKVEETCGCR   WTCPCVCTGS   STRHIVTFDG   1200
                           QNFKLTGSCS      YVLFQNKEQD     LEVILHNGAC   SPGARQGCMK   SIEVKHSALS   1250
                           VELHSDMEVT      VNGRLVSVPY     VGGNMEVNVY   GAIMHEVRFN   HLGHIFTFTP   1300
                           QNNEFQLQLS      PKTFASKTYG     LCGICDENGA   NDFMLRDGTV   TTDWKTLVQE   1350
                           WTVQRPGQTC      QPILEEQCLV     PDSSHCQVLL   LPLFAECHKV   LAPATFYAIC   1400
                           QQDSCHQEQV      CEVIASYAHL     CRTNGVCVDW   RTPDFCAMSC   PPSLVYNHCE   1450
                           HGCPRHCDGN      VSSCGDHPSE     GCFCPPDKVM   LEGSCVPEEA   CTQCIGEDGV   1500
                           QHQFLEAWVP      DHQPCQICTC     LSGRKVNCTT   QPCPTAKAPT   CGLCEVARLR   1550
                           QNADQCCPEY      ECVCDPVSCD     LPPVPHCERG   LQPTLTNPGE   CRPNFTCACR   1600
                           KEECKRVSPP      SCPPHRLPTL     RKTQCCDEYE   CACNCVNSTV   SCPLGYLAST   1650
                           ATNDCGCTTT      TCLPDKVCVH     RSTIYPVGQF   WEEGCDVCTC   TDMEDAVMGL   1700
                           RVAQCSQKPC      EDSCRSGFTY     VLHEGECCGR   CLPSACEVVT   GSPRGDSQSS   1750
                           WKSVGSQWAS      PENPCLINEC     VRVKEEVFIQ   QRNVSCPQLE   VPVCPSGFQL   1800
                           SCKTSACCPS      CRCERMEACM     LNGTVIGPGK   TVMIDVCTTC   RCMVQVGVIS   1850
                           GFKLECRKTT      CNPCPLGYKE     ENNTGECCGR   CLPTACTIQL   RGGQIMTLKR   1900
                           DETLQDGCDT      HFCKVNERGE     YFWEKRVTGC   PPFDEHKCLA   EGGKIMKIPG   1950
                           TCCDTCEEPE      CNDITARLQY     VKVGSCKSEV   EVDIHYCQGK   CASKAMYSID   2000
                           INDVQDQCSC      CSPTRTEPMQ     VALHCTNGSV   VYHEVLNAME   CKCSPRKCSK   2050




286
WHO Drug Information, Vol. 24, No. 3, 2010                                            Recommended INN: List 64




             90
 yttrium ( Y) clivatuzumabum tetraxetanum #
          90
 yttrium ( Y) clivatuzumab tetraxetan         immunoglobulin G1-kappa, anti-[Homo sapiens MUC1 (mucin 1,
                                              polymorphic epithelial mucin, PEM, CD227)], humanized monoclonal
                                                                 90
                                              antibody, yttrium ( Y) radiolabelled tetraxetan conjugate;
                                              gamma1 heavy chain (1-449) [humanized VH (Homo sapiens
                                              IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                                              sapiens IGHG1*03 (120-449)], (222-215')-disulfide with kappa light
                                              chain (1'-215') [humanized V-KAPPA (Homo sapiens IGKV1-13*02
                                              (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -Homo sapiens IGKC*01 (109'-
                                                                                                       90
                                              215')]; (228-228":231-231")-bisdisulfide dimer; yttrium ( Y)
                                              radiolabelled tetraxetan (DOTA) conjugate
            90
 yttrium ( Y) clivatuzumab tétraxétan         immunoglobuline G1-kappa, anti-[Homo sapiens MUC1 (mucine 1,
                                              mucine épithéliale polymorphique, PEM, CD227)], anticorps
                                              monoclonal humanisé, conjugué au tétraxétan et radiomarqué à
                                                         90
                                              l'yttrium ( Y);
                                              chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens
                                              IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                                              sapiens IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne
                                              légère kappa (1'-215') [V-KAPPA humanisé (Homo sapiens IGKV1-
                                              13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -Homo sapiens IGKC*01
                                              (109'-215')]; dimère (228-228":231-231")-bisdisulfure; conjugué au
                                                                                            90
                                              tétraxetan (DOTA) et radiomarqué à l'yttrium ( Y)
       90
 ytrio ( Y) clivatuzumab tetraxetán           inmunoglobulina G1-kappa, anti-[Homo sapiens MUC1 (mucina 1,
                                              mucina epitelial polimórfica, PEM, CD227)], anticuerpo monoclonal
                                              humanizado, conjugado al tetraxetano y radiomarcado con ytrio
                                               90
                                              ( Y);
                                              cadena pesada gamma1 (1-449) [VH humanizada (Homo sapiens
                                              IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                                              sapiens IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena
                                              ligera kappa (1'-215') [V-KAPPA humanizada (Homo sapiens IGKV1-
                                              13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -Homo sapiens IGKC*01
                                              (109'-215')]; dimero (228-228":231-231")-bisdisulfuro; conjugada al
                                                                                             90
                                              tetraxetano (DOTA) y radiomarcado con ytrio ( Y)




                                                                                                               287
Recommended INN: List 64                                             WHO Drug Information, Vol. 24, No. 3, 2010


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQQSGAE VKKPGASVKV SCEASGYTFP SYVLHWVKQA PGQGLEWIGY                                     50
                           INPYNDGTQY NEKFKGKATL TRDTSINTAY MELSRLRSDD TAVYYCARGF 100
                           GGSYGFAYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
                           ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
                           YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK                                     449


                           Light chain / Chaîne légère / Cadena ligera
                           DIQLTQSPSS LSASVGDRVT MTCSASSSVS SSYLYWYQQK PGKAPKLWIY                                     50
                           STSNLASGVP ARFSGSGSGT DFTLTISSLQ PEDSASYFCH QWNRYPYTFG 100
                           GGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
                           VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
                           GLSSPVTKSF NRGEC                                                                          215


                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96             146-202        263-323        369-427
                                        22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L 23'-89'            135'-195'
                                       23'''-89''' 135'''-195'''
                           Inter-H-L 222-215' 222''-215'''
                           Inter-H-H 228-228'' 231-231''


                           Modified residues / Résidus modifiés / Residuos modificados
                                                                                      NH
                           Substitution ratio of 2 to 5 lysyl (K)
                                                                                                              CO2-
                           out of the 90 of the antibody molecule                             N           N
                                                                            H         O
                            6 90
                           N -( Y-yttrium tetraxetan)-L-lysyl                                     90 3+
                                                                                                   Y
                                                                      N       C
                                                                      H               -
                                                                                              N           N
                                                                              O        O 2C                   CO2-

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''




 zoleprodololum
 zoleprodolol              (±)-1-(2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy)-3-[(tert-
                           butylamino)]propan-2-ol

 zoléprodolol              (±)-1-(2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy)-3-[(tert-
                           butylamino)]propan-2-ol

 zoleprodolol              (±)-1-(2-[(3-metoxi-1,2,4-oxadiazol-5-il)metoxi]fenoxi)-3-[(terc-
                           butilamino)]propan-2-ol

                           C17H25N3O5

                                                  H OH
                                                                H
                                          O                     N     CH3

                                                              H3C    CH3
                                          O                                       and enantiomer
                                                                                  et énantiomère
                                                     O                            y enantiómero
                                                         N
                                                N
                                                         OCH3




288
WHO Drug Information, Vol. 24, No. 3, 2010                                                       Recommended INN: List 64



                             AMENDMENTS TO PREVIOUS LISTS
                     MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                         MODIFICACIONES A LAS LISTAS ANTERIORES

Proposed International Non Proprietary Names (Prop. INN): List 50
Dénominations communes internationales proposées (DCI Prop.): Liste 50
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 50
(WHO Drug Information, Vol. 17, No. 4, 2003)


p. 268     alvocidibum
           alvocidib                   replace the graphic formula and the chemical name by the following ones
           alvocidib                   remplacer la formule développée et le nom chimique par les suivants
           alvocidib                   sustitúyase la fórmula desarrollada y el nombre químico por los siguientes

                                       (-)-2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-
                                       4-yl]-4H-1-benzopyran-4-one

                                       (-)-2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-
                                       4-yl]-4H-1-benzopyran-4-one

                                       (-)-2-(2-chlorofenil)-5,7-dihidroxi-8-[(3S,4R)-3-hidroxi-1-metilpiperidin-4-il]-
                                       4H-1-benzopiran-4-ona

                                        H3C
                                              N
                                                       H
                                                       OH Cl
                                                   H
                                        HO              O




                                                  OH    O



Proposed International Non Proprietary Names (Prop. INN): List 63
Dénominations communes internationales proposées (DCI Prop.): Liste 63
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)


p. 43      aganirsenum
           aganirsen                   replace the chemical name by the following
           aganirsén                   sustitúyase el nombre químico por el siguiente

                                       all-P-ambo-P-thiothymidylyl-(3'→'5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-
                                       thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                                       (3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-
                                       deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-
                                       thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                                       (3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-
                                       thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                                       (3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-
                                       thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-
                                       deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-thymidine




                                                                                                                          289
 Recommended INN: List 64                                                       WHO Drug Information, Vol. 24, No. 3, 2010




                                        todo-P-ambo-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-
                                        (3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-
                                        tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-
                                        2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-
                                        tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-
                                        tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-
                                        desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-
                                        desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-
                                        desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-timidina



 p. 46     bixalomerum
           bixalomer                    replace the chemical name by the following
           bixalomère                   remplacer le nom chimique par le suivant
           bixalómero                   sustitúyase el nombre químico por el siguiente

                                        cross linked polymer made of N,N,N',N'-tetrakis(3-aminopropyl)butane-
                                        1,4-diamine N substituted by bivalent substituent groups 2-hydroxypropane-
                                        1,3-diyl and 1-(hydroxymethyl)ethylene (x=20, 45≤y≤50)

                                        N,N,N',N'-tétrakis(3-aminopropyl)butane-1,4-diamine N substituée par les
                                        groupes substituants divalents 2-hydroxypropane-1,3-diyle et
                                        1-(hydroxyméthyl)éthane-1,2-diyle pour former un polymère réticulé (x=20,
                                        45≤y≤50)

                                        N,N,N',N'-tétrakis(3-aminopropil)butano-1,4-diamina N sustituida por los grupos
                                        sustituyentes divalentes 2-hidroxipropano-1,3-diilo y 1-(hidroximetil)etileno para
                                        formar un polímero reticulado (x=20, 45≤y≤50)




 p. 63     delete/supprimer/suprimáse   insert/insérer/insértese
           isopropylis turofexoras      turofexoras isopropylis
           isopropyl de turofexorate    turofexorate d’isopropyle


 # Electronic structure available on Mednet: http://mednet.who.int/
 # Structure electronique disponible sur Mednet: http://mednet.who.int/
 # Estructura electrónica disponible en Mednet: http://mednet.who.int/




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




 290
